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Reports in humans and rodents indicate that immune development may be altered following
perinatal exposure to immunotoxic compounds, including chemotherapeutics, corticosteroids,
polycyclic hydrocarbons, and polyhalogenated hydrocarbons. Effects from such exposure may be
more dramatic or persistent than following exposure during adult life. For example, prenatal
exposure to the insecticide chlordane or to the polycyclic aromatic hydrocarbon benzo[alpyrene
produces what appears to be lifelong immunosuppression in mice. Whether prenatal
immunotoxicant exposure may predispose the organism to postnatal autoimmune disease remains
largely unknown. In this regard, the therapeutic immunosuppressant cyclosporin A (CsA) crosses
the placenta poorly. However, lethally irradiated rodents exposed to CsA postsyngeneic bone
marrow transplant (i.e., during re-establishment of the immune system) develop T-cell-mediated
autoimmune disease, suggesting this drug may produce a fundamental disruption in development
of self-tolerance by T cells. The environmental contaminant 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) crosses the placenta and produces fetal thymic effects in vivo similar to effects of CsA in
fetal thymic organ culture, including inhibited thymocyte maturation and reduced expression of
thymic major histocompatability complex class 11 molecules. These observations led to the
suggestion that gestational exposure to TCDD may interfere with normal development of self-
tolerance. Possibly supporting this hypothesis, when mice predisposed to development of
autoimmune disease were treated with TCDD during gestation, postnatal autoimmunity was
exacerbated. Similar results have been reported for mice exposed to diethylstilbestrol during
development. These reports suggest that prenatal exposure to certain immunotoxicants may play a
role in postnatal expression of autoimmunity. Key words: autoimmune disease, cyclosporin A,
diethylstilbestrol, prenatal, TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin. - Environ Health Perspect
107(suppl 5):687-691 (1999).
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Prenatal immune system ontogenesis and
postnatal functional integrity of the
immune system require a sequential series
ofcarefully timed and coordinated develop-
mental events that begin early in embryonic
life. In experimental animals, the develop-
ing organism has not always been found to
be more sensitive to toxic effects from expo-
sure to physical or chemical agents than the
fully mature individual, but the conse-
quences are often more severe (1-6).
Studies in this relatively new area dealing
with xenobiotic exposure during immune
system organogenesis may be divided into
three basic research initiatives: a) identifi-
cation of sensitive tests and screening pro-
cedures for detecting developmental
immunotoxicants; b) altered postnatal
immunocompetence, including decreased
resistance to infectious disease or neoplasia
after perinatal xenobiotic exposure; and
c) exacerbation of immune-mediated dis-
eases, including hypersensitivity disorders
and autoimmune disease resulting from peri-
natal exposure. Although considerable effort
has been devoted to the first two of these
initiatives, the possibility that developmental
chemical exposure may be related to
increased incidence or severity of aberrant
immunity has received limited attention.
The majority ofavailable data suggesting
a link between prenatal chemical exposure
and enhanced or induced postnatal autoim-
munity concerns estrogenic agents such as
diethylstilbestrol (DES), which alter the pre-
natal hormonal environment and directly tar-
get developing immune cells and halogenated
aromatic hydrocarbons (HAHs) such as
2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD). The therapeutic immunosup-
pressant cyclosporin A (CsA) produces a
T-cell-mediated autoimmunity in rodents by
effects on T-cell development similar to those
caused byTCDD andwill also be discussed.
Consequences of
Developmental
Immunotoxicant Exposure
Numerous published reports indicate that
developmental exposure oflaboratory animals
to immunotoxic chemicals may result in more
severe effects on the immune system than
exposure during adult life. For example, selec-
tive and persistent immune alterations have
been observed in mice following gestational
exposure to the organochlorine insecticide
chlordane, including asignificantdepression of
cell-mediated immunity still present 101 days
after birth (7). Mice exposed to chlordane
during fetal life also display reduced numbers
ofgranulocyte-macrophage colony-forming
units and colony-forming units in the spleen
at 200 days ofage (8) as well as long-term
depression ofboth delayed-type hypersensitiv-
ity and mixed lymphocyte reactivity (9). It is
noteworthy that these immune effects are
either reduced or not observed in adult mice
exposed to chlordane at dose levels equal to
those given to the pregnant mice (8). Similar
results have been reported in mice exposed
during development to benzo[a]pyrene
(B[a]P), a polycyclic aromatic hydrocarbon
(PAH). For instance, offspring ofpregnant
mice treated with B[a]P have been found to
display depressed antibody, graft-versus-host,
and mixed lymphocyte responses at 18
months ofage (10). These mice further exhib-
ited an 8- to 10-fold higher tumor incidence
than control mice that did not experience
in utero B[a]P exposure. Low-level prenatal
exposure to certain HAHs, notably dioxins,
also gives rise to severe, long-lasting immuno-
logic incompetence in rodents (1,11,12).
Collectively, these reports demonstrate that
prenatal exposure to certain immunotoxic
compounds may alter fetal development of
immunity in mice, causing severe and sus-
tained postnatal immunosuppression in the
absence ofovert toxicity. Additional agents
that produce developmental immunotoxicity
in rodents are diverse and include PAHs
other than B[a]P such as 7,12-dimethyl-
benz[a]anthracene, 3-methylcholanthrene;
pesticides other than chlordane such as hexa-
chlorocyclohexane and DDT; polycyclic halo-
genated hydrocarbons such as TCDD; heavy
metals such as cadmium and mercury; hor-
monal substances such as DES, testosterone,
and cortisone; mycotoxins (most notably T2
toxin); and therapeutic agents such as acy-
clovir and cyclophosphamide [Table 1;
reviewed by Holladay and Luster (13)].
Several ofthese agents target the fetal thymus,
producing fetal thymic atrophy as well as
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Table 1. Developmental immunotoxicants.a
Halogenated aromatic hydrocarbons
2,3,7,8-Tetrachlorodibenzo-p-dioxin
Polyhalogenated biphenyls(PCBs, PBBs)
Polycyclic aromatic hydrocarbons
Benzo[alpyrene
Methylcholanthrene
7,12-Dimethylbenz(a)anthracene
Pesticides
Hexachlorocyclohexane
Chlordane
Diazinon
DDT
Carbofuran
Fungicides
Hexachlorobenzene
Heavy metals
Methyl mercury
Lead
Cadmium
Hormonal substances
Estrogens/diethylstilbestrol
Testosterone
Cortisone
Therapeutic agents
Acyclovir
Busulfan
Cyclophosphamide
Mycotoxins
T2 toxin
Abbreviations: PCBs, polychlorinated biphenyls; PBBs, poly-
brominated biphenyls. 'Modified from Holladay and Luster(13).
altered differentiation offetal T-lymphocyte
precursor cells (thymocytes) (summarized in
Table 2). Such chemical insult on thymocyte
maturation during critical periods ofself-
learning may have detrimental consequences
on immune function in postnatal life, includ-
ing possible expression ofautoimmunity (14).
The environmental contaminant TCDD has
probably received the most focused research
attention in this regard.
TCDD: The Prototypic
Halogenated Aromatic
Hydrocarbon
The chemical agent most studied for
suppressive effects on the immune system is
undoubtedly TCDD. This compound has
also recently become suspect for producing
changes in immune cells and immune support
cells, which may potentiate development of
autoimmune diseases. Greenlee et al. (15) and
Schuurman et al. (16) described targeting of
thymic epithelium by TCDD, leading to sug-
gestions that TCDD may have the potential
to alter critical epithelium-dependent selective
events in the thymus through which develop-
ing thymocytes expressing autoreactive T-cell
receptors (TCRs) are deleted. DeWaal et al.
(17) further observed altered thymic epithelial
distribution ofmajor histocompatability com-
plex (MHC) class II molecules in TCDD-
treated mice, an effect that was hypothesized
as having potential to cause defective
thymocyte-epithelial cell interactions.
Table2. Immunotoxicants producing fetal thymic atrophy and impairedthymocyte differentiation in mice.a
Immunotoxicant Exposure regimen
2,3,7,8-Tetrachlorodibenzo-p-dioxin 1.5-3.0 mg/kg/dayfrom gd 6-14
3,3',4,4'-Tetrachlorobiphenyl 6-16 mg/kg on gd 12
Diethylstilbestrol 3-8 mg/kg/dayfrom gd 10-16
Ethylene glycol monomethyl ether 100-200 mg/kg/dayfromgd 10-17
Benzo[alpyrene 50-150 mg/kg/day from gd 14-17
7,12-Dimethylbenz[alanthracene 10-25 mg/kg/dayfrom gd 14-17
T2 mycotoxin 1.2-1.5mg/kg/dayfrom gd 14-17
gd, gestational day(s). Modified from Holladay and Luster160).
Specifically, MHC class I anddass II molecules
act as thymic self-antigen-presenting molecules
in a process whereby thymocytes expressing
TCRs with high affinity to self-antigen are
eliminated (negative selection). It has also
been noted that similar patterns ofinhibited
thymic T-cell differentiation occur sponta-
neously in autoimmune mice (18), in
TCDD-treated mice (14), and in mice
treated in vivo with monoclonal antibodies to
MHC class I and class II molecules (19), sug-
gesting the importance ofthese MHC mole-
cules in thymocyte differentiation. TCDD
was recently found to downregulate expres-
sion ofan MHC dass I gene (Q1b) in a mouse
hepatoma cell line (20). Specifically, these
authors observed that MHC Qlb cDNA
encoded for the a3 domain and transmem-
brane domain of the Qlb class I protein,
implying that the MHC gene product could
interact with P2-microglobulin. These obser-
vations led to the hypothesis that the MHC
Qlb molecule downregulated by TCDD may
function in antigen presentation (20).
Together, these effects of TCDD on
thymocytes, thymic epithelium, and MHC
molecules associated with antigen presentation
raise questions regarding the ability ofTCDD
to alter normal development ofself-tolerance
in T cells in a way that may increase expressed
autoimmunity. The popliteal lymph node
assay has been proposed by some as a tool to
predict autoimmune reactions induced by
chemicals (21) and recently was found to
elicit a positive response in male rats injected
with TCDD (22). Based on this observation
(22) these authors joined others suggesting
that TCDD may have the potential to induce
or exacerbate autoimmunelike reactions.
Because chemical-induced altered
intrathymic negative selection ofpotential
autoreactive T cells may result in increased
release ofsuch cells to the periphery, other
investigators have looked for emergence ofT
cells carrying TCR-variable regions associated
with self-reactivity in TCDD-treated animals.
The TCR-variable , (Vp) chains are usually
deleted in the thymus by reaction with self-
MHC and minor lymphocyte stimulatory
antigens (23,24) and have been associated
with autoimmunity in some experimental
mouse models (25). Therefore, deHeer et al.
(26) examined the thymus, spleen, and
mesenteric lymph nodes ofadult mice dosed
with TCDD for autoreactive mature V,B6+
Tcells andwere not able to demonstrate emer-
gence ofsuch cells. However, in related studies
Silverstone et al. (27) found that both TCDD
and estradiol induce extrathymic T-cell differ-
entiation in the liver ofyoung adult mice, and
that such extrathymic cells expressed elevated
levels ofVp+ TCR Such an increase in T cells
associated with autoreactivity has been sug-
gested as a mechanism bywhich estrogen may
promote autoimmunity (23). Silverstone et al.
(27) have similarly suggested that these find-
ings with TCDD (increased extrathymic
autoreactive T cells) may relate to ability of
this HAH to promoteautoimmunity.
Effects ofTCDD on T-Cell
Development: Comparison
to Cyclosporin A
The demonstration ofhigh sensitivity ofthe
developing immune system to TCDD, cou-
pled with evidence that TCDD exposure in
adult animals may result in increased expres-
sion ofautoimmune disease, has raised ques-
tions regarding possible relationships
between prenatal exposure to TCDD and
increased postnatal autoimmunity. Low-level
maternal TCDD exposure produces fetal
thymic atrophy as well as inhibition ofthy-
mocyte differentiation (Table 3). Fetal liver
T-progenitor cells seed the fetal thymus and
are initially double negative with respect
to CD4 and CD8 surface antigens.
Subsequently, thymocytes develop sequen-
tially through immature CD810 and CD4+8+
double-positive stages in the thymic cortex to
mature CD4+ SP or CD8+ SP thymocytes in
the thymic medulla by gestational days
18-19 (28,29). TCDD produces a signifi-
cant maturational delay in fetal thymocyte
development, as evidenced by these CD4
and CD8 surface antigens. This delay has
been described as similar to the maturational
inhibition produced in fetal thymic organ
culture by the therapeutic immunosuppres-
sive drug CsA (14). Fetal thymic organ cul-
ture was used rather than in vivo exposure to
study the effect ofCsA on developing Tcells
because CsA crosses the placenta poorly
(30). Fetal mouse exposure to TCDD or ex
vivo exposure offetal mouse thymi to CsA
decreased the percentage ofdouble-positive
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Table 3. Effect ofTCDD on fetal thymic weight and thymocyte CD4and CD8 antigen expression.abc
CD markerexpression(% positive) Thymicweight/
Treatment CD4+8- CD4+8+ CD4-8- CD4-8+ bodyweight(%)
Vehicle 1.8 ±0.2 69.1 ± 1.2 21.1 ±0.7 8.1 ±0.7 0.24
1.5 pg/kg 1.5 ± 0.1 52.6 ± 2.5* 30.3 ± 1.8* 15.5 ± 0.9* 0.14*
3.0 pg/kg 2.0 ±0.2 43.2 ± 4.5* 37.3 ± 3.7* 17.5± 0.9* 0.10*
TCDD, 2,3,7,8-tetrachlorodibenzo-p-dioxin. aCD4 and CD8 surface antigen expression was determined in fetal mice on gestational day
(gd) 18 after matemal exposure to 1.5 or 3.0 pg/kg/day TCDD from gd 6-14. bValues represent mean ± SEM of 5 mice pertreatment
group. 0Modified from Holladay etal. (6). *p<0.05versus vehicle controls.
cells (the most mature phenotype present in
significant numbers in the end-gestation
mouse fetus) and increased the percentage of
both double-negative cells and immature
(i.e., TCR-) CD8IO thymocytes. Any intrinsic
(hormonal) or extrinsic (chemical) insult on
thymocyte maturation during critical periods
ofthymocyte selection for self-recognition
may have significant and detrimental conse-
quences on immune function in postnatal life
(14). Thus, this pattern ofinhibition by
TCDD or CsAraised questions about interfer-
ence with neonatal development oftolerance
bythesechemicals.
In rodents, CsA also reduces MHC class
II antigen expression in the thymus (31), an
effect that was associated with development
ofautoimmune disease in Lewis rats exposed
to CsA following lethal irradiation and syn-
geneic bone marrow reconstitution (32).
Specifically, these studies demonstrated a
T-cell-mediated autoimmune disease in the
rats treated with CsA after bone marrow
transplant, manifested as a syngeneic graft-
versus-host response (SGVHR). Briefly, the
development of a chronic graft-versus-
host-like disease, typical of that seen in
rodents or humans following allogeneic mar-
row transplantation, was observed in the
CsA-exposed rodents that had received syn-
geneic bone marrow transplants (33). This
observation ofan SGVHR was the demon-
stration of an immune system rejecting
genetic self (i.e., autoimmunity), indicating
that CsA produced a fundamental disruption
in development of self-tolerance. These
authors demonstrated that the CsA-induced
autoreactivity was transferred with the CD8+
subpopulation ofT cells, suggesting that CsA
interfered with deletion ofthese cells during
the establishment ofa new immune system in
the irradiated animals (33).
Model Development
The use ofa bone marrow transplant model
in syngeneic animals to demonstrate CsA-
induced interference with normal establish-
ment ofself-tolerance may have interesting
implications for future studies that consider
relationships between perinatal exposure to
environmental chemicals and subsequent
development of autoimmune disease.
Specifically, the SGVHR model mimics fetal
immune development in many ways; in both
cases a new immune system must be estab-
lished from a limited population of
hematopoietic progenitor cells. In either situ-
ation (developing fetus or adult transplant),
this process requires that large numbers of
immune cells be ushered through the normal
selective processes governing establishment of
self-recognition. It is reasonable to expect that
a chemical effect on these selective processes
may be more profound (thus easier to iden-
tify) in these developmental models than in
an adult model in which the immune system
is already established and substantially fewer
immune cells are undergoing selection.
Further, a syngeneic bone marrow transplant
model is not limited by placental transfer of
chemical. Thus the model may again facilitate
identification ofagents causing limited but
real effects on developing immune cells. For
example, placental transfer ofCsA appears to
be negligible (34), and ex vivo models such as
fetal thymic organ culture have been used to
study possible effects ofthis drug on immune
development (30). Considerablyless than 1%
of the maternal dose ofTCDD crosses the
placenta in the mouse (35), yet this fetal
exposure causes significant and diverse effects
on thedeveloping immune system (14,36).
The demonstration that CsA produces
autoimmune disease in rodents byalteringthy-
mocyte differentiation during negative selec-
tion of autoreactive T cells, an effect that
appears to be related to downregulation of
thymic MHC class II molecules, brings up
interesting questions regarding TCDD.
TCDD produces an inhibition offetal thymo-
cyte differentiation very similar to that seen in
fetal thymic organ cultures exposed to CsA
and also interferes with expression ofthymic
MHC dass II molecules (17). Thus, TCDD
produces effects similar to those that have been
related to production ofautoimmune disease
in CsA-treated animals. Whether these effects
may be related to increased autoimmune dis-
ease in TCDD-exposed rodents or humans is
presently not known. However, Silverstone et
al. recently found that monthly exposure of
young adult SNFI mice to TCDD resulted in
the appearance ofautoimmune nephritis in
males in the first 6 months oflife (37). These
authors further reported that a single fetal
exposure to TCDD in NZB x SWR
(SNFI) mice significantly reduced the
time to postnatal onset ofautoimmune nephri-
tis in male offspring. Together, these data sug-
gest that TCDD may have the potential to
induce autoimmune disease in genetically pre-
disposed animals. It may therefore be ofinter-
est to evaluate the effect of TCDD on
development ofautoimmune responses in syn-
geneic rodents after irradiation and bone mar-
row transplantation, where placental transfer
does not limit exposure of the developing
immune system to TCDD.
Diethyistilbestrol: A Model
Estrogen
The regulatory actions ofestrogenic steroids
on immune function in adult animals are well
documented but remain poorly understood.
A role for endogenous estrogen and the devel-
opment ofautoimmune disease exists, as well
as a correlation between increased serum
estradiol levels (e.g., during pregnancy) and
infections resulting from depression ofcell-
mediated immunity (38,39). Administration
ofpharmacologic or suprapharmacologic lev-
els ofsteroidal and nonsteroidal estrogenic
compounds further results in numerous alter-
ations ofimmune function, particularlywhen
administered perinatally during lymphoid
organ organogenesis. Effects ofsuch adminis-
tration in rodents include myelotoxicity
(40,41), suppression ofcell-mediated immu-
nity (42,43), pronounced thymic atrophy
(44,45), depressed activity of natural killer
cells (46,47), and stimulation ofthe reticulo-
endothelial system (48,49). Studies of
women exposed in utero to DES, a synthetic
nonsteroidal compound possessing estrogenic
activity, suggest possible adverse affects on the
postnatal human immune system. For
instance, altered function ofT lymphocytes
and natural killer cells in women exposed to
DES in utero has been reported (50,51) as
well as an increased incidence ofautoimmune
diseases (52). Although it appears that estro-
gens mediate certain oftheir immune effects
at the thymic level by altering thymic epithe-
lium-dependent mechanisms (53), little is
understood about mechanisms by which
estrogenic chemicals may influence immune
responses to foreign orself-antigens.
An altered prenatal hormonal environment
has been associated with increased risk of
developing autoimmune disease in mice (54).
Ithas also been suggestedthathumansexposed
in utero to DES may display a hyperreactive
immune response (55). A retrospective study
ofDES-exposed (1,711 individuals) and unex-
posed (922 individuals) cohorts examined the
possibility that prenatal DES may affect the
prevalence ofautoimmune disease and found a
positive correlation when autoimmune diseases
were grouped (4). Specifically, the overall
frequency ofany autoimmune disease among
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exposed women was 28.6 per 1,000 compared
to 16.3 per 1,000 among the controls (signifi-
candydifferent atp = 0.02). Autoimmune dis-
eases evaluated included systemic lupus
erythematosus, scleroderma, Graves disease,
Hashimoto thyroiditis, pernicious anemia,
myasthenia gravis, thrombocytopenic purpura,
rheumatoid arthritis, regional enteritis, chronic
ulcerative colitis, multiple sclerosis, chronic
lymphocytic thyroiditis, Reiter syndrome, and
optic neuritis. When these autoimmune dis-
eases were considered individually, however,
only Hashimoto thyroiditis occurred signifi-
candy more often in the exposed women (p =
0.04). A similar evaluation of 1,173 humans
exposed to DES during development (1,079
daughters and 94 sons) found increased
asthma, arthritis, and diabetes mellitus com-
pared to prevalence rates for these diseases in
the general population (56). However, in a
more recent study evaluating rates ofallergy,
infection, and autoimmune disease in DES-
exposed sons anddaughters (253 men and 296
women) matchedwith similar unexposed indi-
viduals (241 men and 246 women), no differ-
ences in disease occurrence were detected (57).
These authors conduded that a larger sample
was needed to evaluate DES-associated risk of
autoimmunity, since autoimmune diseases are
relativelyrare in thehuman population.
Thus preliminary studies of humans
exposed before birth to DES suggest the pos-
sibility ofpostnatal immune alterations,
including increased autoimmune disease.
Continued surveillance of DES sons and
daughters will be required for more definitive
statements but will become more difficult as
this cohort ages and members are lost.
Laboratory rodent studies will therefore be
important to determine ifprenatal exposure
to chemicals such as DES may alter develop-
ment ofimmune cells in such away as to pre-
dispose an individual to expression of
postnatal autoimmunity and to answer ques-
tions regarding specific immune cell targets
and mechanisms ofaction.
Hybrid B6C3F1 (C57B1/6N x C3H)
mice exposed to 8 pg/kg/day DES from days
10-16 of gestation displayed significant
thymic hypocellularity in late gestation as
well as limited but significant inhibition of
thymocyte maturation (Table 4) (58).
Thymic involution in these studies was
related to a reduction by DES offetal liver
prothymocytes responsible for colonizing the
fetal thymus. These authors also reported that
fetal liver prothymocytes expressed estrogen
receptors at about 290 fmol/100 pg DNA, a
level approximately half that found in the
uterus and sufficient to suggest an estrogen-
responsive cell. These and other reports indi-
cate the developing mouse immune system is
sensitive to estrogen exposure, and that such
exposure may contribute to postnatal
Table 4. Effect of DES on fetal thymocyte cellularity and CD4and CD8 antigen expression.abc
CD marker expression (% positive) Cellularity
Treatment CD48- CD4+8+ CD48 CD4-8+ (x 106)
Vehicle 4.1 ± 0.2 71.4 ± 0.7 22.0 ± 0.7 2.7 ± 0.2 40.4 ± 2.6
3 mg/kg 3.2 ±0.4 64.0 ± 2.5* 28.8± 2.5* 4.0± 0.3* 18.9 ±1.9*
8 mg/kg 4.0 ± 0.4 63.6 ± 1.6* 29.2 ± 1.5* 3.3 ± 0.3 8.7 ± 1.9*
DES, diethylstilbestrol. 'CD4and CD8 surface antigen expression was determined in fetal mice on gestational daylgdl 18 aftermater-
nal exposure to 3 or 8 pg/kg/day DES from gd 10-16. bValues represent mean ± SEM of 5 mice per treatment group. cModified from
Holladay et al. (58). *p< 0.05versus vehicle controls.
immunosuppression (13). However, as with
most ofthe well-established rodent develop-
mental immunotoxicants, very limited infor-
mation is available addressing possible
relationships between gestational DES expo-
sure and altered expression of postnatal
autoimmune disease.
A single fetal exposure to DES in SNF1
mice induced autoimmune lupuslike nephri-
tis in male offspring between 5 and 10
months of age (37). Female SNF1 mice
develop this autoimmune syndrome sponta-
neously in their first year oflife; however,
male mice do not display significant autoim-
munity before 1 year ofage. These data sug-
gest that pharmacologic exposure to DES
may contribute to early expression ofautoim-
munity in genetically predisposed mice, and
that autoimmune rodent models such as the
SNF1 model may prove valuable for identifi-
cation ofbiologic markers for human risk
assessment. Because autoimmune diseases are
multifactorial (genetic, environmental, hor-
monal, infectious) (59), clearly, continued
research will be required to determine possi-
ble relationships between prenatal estrogen
exposure and postnatal development of
autoimmune disease.
Conclusion
It has been repeatedly demonstrated that
the developing immune system is highly
sensitive to known adult immunotoxicants
that cross the placenta. However, the devel-
opmental immunotoxicity data presently
available in the literature are almost exclu-
sively limited to postnatal immunosuppres-
sion (rather than hypersensitivity or
autoimmunity). Indeed, very few immuno-
toxicants (e.g., DES, TCDD) that have
been associated with induced or exacerbated
autoimmunity in adult animals have been
evaluated for similar effects following gesta-
tional exposure. Preliminary data suggest
that both DES and TCDD may alter devel-
opment of the immune system in mice
genetically predisposed to autoimmune dis-
ease, causing earlier expression of autoim-
munity. DES is a nonsteroidal estrogen, and
as such is often used to study the effects on
immune function of both endogenous
estrogens and environmental compounds
possessing estrogenic activity. TCDD is the
most biologically potent member of a
family of polyhalogenated aromatic hydro-
carbons that contains other important
environmental contaminants such as poly-
chlorinated biphenyls and halogenated
dibenzofurans. Given the large number of
estrogenic environmental contaminants
(including many agents presently grouped
under the umbrella ofendocrine-disrupting
compounds) and the extent ofenvironmen-
tal contamination with TCDD and TCDD
congeners, the importance ofdetermining if
these agents (acting alone or in mixtures)
may alter normal development of the
immune system in a way that may con-
tribute to increased autoimmune disease in
humans is becoming evident.
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